Cavallin Francesco, Alfieri Rita, Scarpa Marco, Cagol Matteo, Ruol Alberto, Fassan Matteo, Rugge Massimo, Ancona Ermanno, Castoro Carlo
Esophageal and Digestive Tract Surgical Unit, Regional Centre for Esophageal Disease, Veneto Institute of Oncology IOV IRCCS, Padova, Italy.
3rd Surgical Clinic, Azienda Ospedaliera di Padova, Padova, Italy.
BMC Surg. 2017 May 2;17(1):49. doi: 10.1186/s12893-017-0247-5.
Nodal skip metastasis is a prognostic factor in some sites of malignancies, but its role in esophageal cancer is still unclear. The present study aimed to investigate occurrence and effect of nodal skip metastases in thoracic esophageal squamous cell carcinoma.
All 578 patients undergoing esophagectomy for thoracic esophageal squamous cell carcinoma at the Center for Esophageal Diseases located in Padova between January 1992 and December 2010 were retrospectively evaluated. Selection criteria were R0 resection, pathological M0 stage and pathological lymph node involvement. Patients receiving neoadjuvant therapy were excluded.
The selection identified 88 patients with lymph node involvement confirmed by pathological evaluation. Sixteen patients (18.2%) had nodal skip metastasis. Adjusting for the number of lymph node metastases, patient with nodal skip metastasis had similar 5-year overall survival (14% vs. 13%, p = 0.93) and 5-year disease free survival (14% vs. 9%, p = 0.48) compared to patients with both peritumoral and distant lymph node metastases. The risk difference of nodal skip metastasis was: -24.1% (95% C.I. -43.1% to -5.2%) in patients with more than one lymph node metastasis compared to those with one lymph node metastasis; -2.3% (95% C.I. -29.8% to 25.2%) in middle thoracic esophagus and -23.0% (95% C.I. -47.8% to 1.8%) in lower thoracic esophagus compared to upper thoracic esophagus; 18.1% (95% C.I. 3.2% to 33.0%) in clinical N0 stage vs. clinical N+ stage.
Nodal skip metastasis is a common pattern of metastatic lymph involvement in thoracic esophageal squamous cell carcinoma. However, neither overall survival nor disease free survival are associated with nodal skip metastasis occurrence.
淋巴结跳跃转移是某些部位恶性肿瘤的一个预后因素,但其在食管癌中的作用仍不清楚。本研究旨在探讨胸段食管鳞状细胞癌中淋巴结跳跃转移的发生情况及其影响。
对1992年1月至2010年12月期间在帕多瓦的食管疾病中心接受胸段食管鳞状细胞癌食管切除术的578例患者进行回顾性评估。选择标准为R0切除、病理M0期和病理淋巴结受累。排除接受新辅助治疗的患者。
经病理评估,筛选出88例有淋巴结受累的患者。16例患者(18.2%)有淋巴结跳跃转移。在调整淋巴结转移数量后,与肿瘤周围和远处淋巴结均有转移的患者相比,发生淋巴结跳跃转移的患者5年总生存率(14%对13%,p = 0.93)和5年无病生存率(14%对9%,p = 0.48)相似。淋巴结跳跃转移的风险差异为:与有一个淋巴结转移的患者相比,有一个以上淋巴结转移的患者为-24.1%(95%置信区间-43.1%至-5.2%);与胸段食管上段相比,胸段食管中段为-2.3%(95%置信区间-29.8%至25.2%),胸段食管下段为-23.0%(95%置信区间-47.8%至1.8%);临床N0期与临床N+期相比为18.1%(95%置信区间3.2%至33.0%)。
淋巴结跳跃转移是胸段食管鳞状细胞癌转移性淋巴结受累的一种常见模式。然而,总生存率和无病生存率均与淋巴结跳跃转移的发生无关。